koryu

crispr crispr

Длинная
koryu Обновлено   
NASDAQ:EDIT   Editas Medicine, Inc.
15
Follow up idea, see related idea

After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.

In case of bull market, we got the possible pitchfork
Комментарий:
and back above IPO!!! i love it <3
Комментарий:
look for rsi breakout into new highs, consolidation above 18$ would confirm reversal.

Комментарий:
Wyckoff scenario
Комментарий:
wyckoff playing out nicely, can buy on dips for reaccumulation 16-17$ range
trailing stop below pitchfork, this stock keeps giving for weeks now with great volatility
Комментарий:
made a little indicator to compare EDIT price with the BTK biotech index
At ipo the indicator is 0, values below 0 indicates that EDIT is undervalued compared to biotech index, values over 0 indicates EDIT is overvalued compared to biotech index. Also showing the MA20 of this line (black).

Комментарий:
Комментарий:
crispr again in the news after
Комментарий:
crispr again on all news sites after National Academy of Sciences releases Report "Human Genome Editing: Science, Ethics, and Governance"
Комментарий:
CRISPR patent goes to Broad Institute of Cambridge -> EDIT www.technologyreview...-to-broad-institute/
Комментарий:
pitchfork still intact!

wyckoff scenario also playing out as expected :-)

Комментарий:
Editas Medicine announces that its offering of 4M shares priced at $22.50 per share.
seekingalpha.com/new...-prices-90m-offering

resistance 0.5 fib keylevel at 28.20
Support 20.00-22.50
Комментарий:
doubled my position here
Комментарий:
this should be a bear trap, new chart on linear scale

Отказ от ответственности

Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.